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Antidepressant treatment and the risk of fatal and non-fatal self
harm in first episode depression: nested case-control study
Carlos Martinez, Stephan Rietbrock, Lesley Wise, Deborah Ashby, Jonathan Chick, Jane Moseley, Stephen Evans,
David Gunnell
Abstract
Objective To compare the risk of non-fatal self harm and
suicide in patients taking selective serotonin reuptake inhibitors
(SSRIs) with that of patients taking tricyclic antidepressants, as
well as between different SSRIs and different tricyclic
antidepressants.
Design Nested case-control study.
Setting Primary care in the United Kingdom.
Participants 146 095 individuals with a first prescription of an
antidepressant for depression.
Main outcome measures Suicide and non-fatal self harm.
Results 1968 cases of non-fatal self harm and 69 suicides
occurred. The overall adjusted odds ratio of non-fatal self harm
was 0.99 (95% confidence interval 0.86 to 1.14) and that of
suicide 0.57 (0.26 to 1.25) in people prescribed SSRIs
compared with those prescribed tricyclic antidepressants. We
found little evidence that associations differed over time since
starting or stopping treatment. We found some evidence that
risks of non-fatal self harm in people prescribed SSRIs
compared with those prescribed tricyclic antidepressants
differed by age group (interaction P = 0.02). The adjusted odds
ratio of non-fatal self harm for people prescribed SSRIs
compared with users of tricylic antidepressants for those aged
18 or younger was 1.59 (1.01 to 2.50), but no association was
apparent in other age groups. No suicides occurred in those
aged 18 or younger currently or recently prescribed tricyclic
antidepressants or SSRIs.
Conclusion We found no evidence that the risk of suicide or
non-fatal self harm in adults prescribed SSRIs was greater than
in those prescribed tricyclic antidepressants. We found some
weak evidence of an increased risk of non-fatal self harm for
current SSRI use among those aged 18 or younger. However,
preferential prescribing of SSRIs to patients at higher risk of
suicidal behaviour cannot be ruled out.
Topic: 83; 576; 299; 208
Introduction
Since the introduction of selective serotonin reuptake inhibitor
(SSRI) antidepressants, concerns have been that these drugs may
increase the risk of suicidal behaviour.1–3 Although analyses of
data in adults have not consistently shown any influence on
suicide or self harm from use of SSRIs,4 randomised controlled
trials in young people indicate that these drugs may increase the
risk of suicidal thoughts and self harm in those aged under 19.5 6
Ecological studies provide mixed evidence on the risks and
benefits of SSRIs—some show that increases in SSRI prescribing
are associated with reductions in suicide rates in the population;
others show the opposite.4
The most comprehensive studies of suicidal behaviour to
date are based on the General Practice Research Database.7 8 The
first study contrasted the risks of suicide in people taking antide-
pressants commonly prescribed between 1988 and 1993.
Although this study found some evidence of an increased risk of
suicide among people prescribed fluoxetine,7 it was difficult to
interpret because the drug’s safety in overdose may have led to
selective prescription to people at risk of self harm. Another
study8 compared the risks for suicide and non-fatal suicidal
behaviour between people prescribed fluoxetine, paroxetine,
amitriptyline, and dothiepin in 1993 to 1999. No notable differ-
ences were found between the drugs in risk for fatal or non-fatal
suicidal behaviour. The study was not restricted to patients
prescribed antidepressants for the treatment of depression,
making comparisons between individual SSRIs and tricyclic
antidepressants more liable to confounding.
We report a nested case-control study, based on the General
Practice Research Database, of patients with a new diagnosis of
depression who were prescribed antidepressants for the first
time between 1995 and 2001. We compared the risk of non-fatal
self harm and suicide in association with the use of SSRIs and
tricyclic antidepressants.
Methods
Materials
The General Practice Research Database contains anonymised
clinical records from primary care in the United Kingdom.9 Our
study cohort came from this database and comprised patients
aged 90 years or younger with a first recorded prescription for
antidepressants between 1 January 1995 and 31 December 2001.
The date of the first prescription defined entry to the cohort.
Members of the cohort were required to have contributed a
minimum of 365 days to the database before their first recorded
prescription for antidepressants and to have received a diagnosis
of depression in the 180 days before or 90 days after entry to the
cohort. Follow up ended with the earliest of either an episode of
suicidal behaviour, the end of the first treatment episode, the end
date of the study, or when the patient left the practice. People
with an episode of non-fatal self harm were not censored in
analyses with suicide as the end point.
A classification system for the severity of depression, the method used
to measure exposure to antidepressants, and supplemental tables are on
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We identified depression by a set of Read and Oxford Medi-
cal Information System (OXMIS) medical terms indicative of
depression, bipolar disorder, or dysthymic disorder. We classed
severity of depression as mild,moderate, or severe (see bmj.com).
We categorised antidepressants into three classes: tricyclic
and related antidepressants (amitriptyline, amoxapine, clomi-
pramine, dosulepin or dothiepin, doxepin, imipramine, lofe-
pramine, nortriptyline, trimipramine, maprotiline, mianserin,
and trazodone), SSRIs (citalopram, fluoxetine, fluvoxamine, par-
oxetine, and sertraline), and other antidepressants (flupenthixol,
mirtazapine, reboxetine, tryptophan, venlafaxine, and the
monoamine oxidase inhibitors phenelzine, isocarboxazid, tranyl-
cypromine, and moclobemide).
We studied the two outcomes of non-fatal self harm and sui-
cide. We identified cases of suicide from a list of OXMIS or Read
medical terms, review of all free text entries for patients who had
died of any cause, and death certificates when available (around
60% of cases). Using this information we assessed the likelihood,
the method, and the date of suicide.
We identified cases of non-fatal self harm (drug overdose,
deliberate self laceration, poisoning, and non-fatal suicide
attempts using other methods) by using relevant OXMIS or
Read medical terms and review of the patient’s free text notes.
We selected a random sample of up to 20 controls for each
case from the cohort, matching for sex, year of birth within one
year, and duration of cohort membership to the nearest day for
participants with membership of less than 60 days, nearest 10
days if membership was 60 to 365 days, and one month if cohort
membership was more than one year.We derived the duration of
prescriptions from the quantity of drug prescribed and the daily
dose plus an additional seven day washout period (see bmj.com).
Data analysis
We classified the cases and controls as currently or previously
exposed to an SSRI, tricyclic antidepressant, or other antidepres-
sant, or co-exposed to more than one antidepressant, according
to the exposure status on the index day (day of self harm or sui-
cide or equivalent control day). We standardised the incidence
rates for non-fatal self harm and suicide to the UK population in
2001.10 11
We assessed risks associated with “current exposure.” We
used multivariable conditional logistic regression to estimate
adjusted odds ratios and 95% confidence intervals. In the models
that compared non-fatal self harm associated with different
classes of antidepressants, we prespecified monotherapy with a
tricyclic antidepressant as the reference group. We used
monotherapy with paroxetine and monotherapy with dothiepin
as the reference categories for the respective comparisons within
drug classes. We controlled for severity of depression, referral to
a psychiatrist or psychologist, history of non-fatal self harm,
diagnosis of or treatment for anxiety or panic disorder,
schizophrenia, antipsychotic drugs, drug misuse, alcohol misuse,
current lithium treatment, number of antidepressants prescribed
in the previous year, and time difference between diagnosis of
depression and start of treatment.
We investigated whether risk varied in relation to duration of
current use of antidepressants, time since stopping treatment,
and age at entry to the cohort (10-18, 19-30, and > 30). We
defined the youngest age group on the basis that a possible
increased risk of suicidal behaviour has been shown among peo-
ple aged up to and including 18 who have been prescribed
SSRIs. This age categorisation of paediatric patients is in keeping
with international regulatory guidelines.12 The General Practice
Research Database does not hold the date of birth but only the
year of birth, and therefore the age at the event date could fluc-
tuate by up to one year from the real age.
We stratified the duration of exposure (days) to antidepres-
sants into four categories ( < 14, 15-30, 31-60, > 60) after the
start of treatment with antidepressants. Time since discontinua-
tion was stratified into the same four categories according to the
end date of the prescription. In all comparisons, we compared
SSRI monotherapy with tricylic antidepressant monotherapy for
the same duration of either current or past exposure. We used
likelihood ratio tests to carry out heterogeneity tests. We do not
present odds ratios based on fewer than three cases or controls
in either group. We used Stata, release 8 (College Station, TX:
StataCorp), for all analyses.
Results
Our study cohort included 146 095 patients with a first prescrip-
tion for an antidepressant for depression. These patients
contributed 62 224 person years of follow up to the cohort (see
bmj.com). Table 1 lists the characteristics of the participants, clas-
sified according to the first antidepressant prescribed. Almost
twice as many women as men received antidepressants. SSRIs
were the most commonly prescribed antidepressants. People
prescribed SSRIs tended to be younger and more often had a
history of self harm and referral to psychiatrists than those pre-
scribed tricyclic antidepressants.
Table 2 shows data on exposures to antidepressants by age
group. The strongest predictors of non-fatal self harm were a
history of self harm, referral to a psychiatrist, alcohol misuse, and
drug misuse. The strongest predictors for suicide were a history
of non-fatal self harm, antipsychotic therapy, number of antide-
pressants prescribed in the previous year, alcohol misuse, and
referral to a psychiatrist (table 3).
Over the study period, 1968 people had a recorded an
episode of non-fatal self harm: 1344 were exposed to
antidepressant medication at the time, and 624 had stopped
treatment before the episode. Drug overdose accounted for most
episodes of non-fatal self harm (81%). The incidence rate of
non-fatal self harm, standardised by age and sex, per 100 000
person years of follow up among people prescribed antidepres-
sants was 2894 (95% confidence interval 2618 to 3170). The rate
per 100 000 person years for men was 2834 (2579 to 3089) and
for women was 2952 (2471 to 3432).
Overall, 69 suicides took place (56 men, 13 women); 36 of
those people were taking antidepressants at the time of death.
The overall standardised incidence rate for suicide was 62 (40 to
85) per 100 000 person years; in men this was 117 (72 to 163)
and in women 9 (1 to 18).
Table 4 shows the association of current antidepressant use
with non-fatal self harm and suicide for all ages. The adjusted
odds ratio for non-fatal self harm among SSRI users compared
with users of tricyclic antidepressants was 0.99 (0.86 to 1.14). We
found no evidence that the risk of non-fatal self harm varied
among the different individual SSRIs or tricyclic antidepressants
(P = 0.35 and P = 0.69, respectively) and no evidence of an
increased risk of suicide associated with use of SSRIs compared
with tricyclic antidepressants (odds ratio 0.57, 0.26 to 1.25).
We found borderline evidence that the risk of non-fatal self
harm (P for interaction = 0.05), but not suicide (P for
interaction = 0.73), differed between the different antidepressant
categories in relation to time since starting therapy (table 5). This
association showed no clear pattern.
We found evidence of a difference in risk of non-fatal self
harm for current SSRI users compared with current users of tri-
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cyclic antidepressants in relation to age (P for interaction = 0.02),
with an increased risk associated with SSRI use among those
aged 18 or younger (odds ratio 1.59, 1.01 to 2.50), but not in 19
to 30 year olds (1.04, 0.82 to 1.31) or those younger than 30
(0.86, 0.71 to 1.04; table 6).
In people aged 18 or younger, we found no evidence of any
difference in risk of non-fatal self harm between individual tricy-
clic antidepressants, but among SSRIs (figure), the greatest risk
was in relation to paroxetine use.
The risk of non-fatal self harm or suicide did not seem to dif-
fer between or within antidepressant classes according to the
time since stopping treatment (see bmj.com).
Discussion
In patients with newly diagnosed depression treated with antide-
pressants for the first time, we have found no evidence that the
risk of suicide in people currently prescribed SSRIs is higher
than in those prescribed tricyclic antidepressants.
Likewise, we found no differences overall in the risk of non-
fatal self harm between people prescribed SSRIs and those pre-
scribed tricyclic antidepressants. However, we found some
evidence that the risk of non-fatal self harm among people pre-
scribed SSRIs differed with age. In patients aged 18 or younger,
but not older subjects, risks were higher in people prescribed
SSRIs than with tricyclic antidepressants. Consistent with the
findings of a recent study by Jick et al,8 we found no overall evi-
dence of significant variability in the risk of non-fatal self harm
between substances or between drug classes associated with time
since starting antidepressant therapy. We also found no evidence
overall of a difference between SSRIs and tricyclic antidepres-
sants in the risk of non-fatal self harm or suicide on stopping
treatment. In young people (younger than 18), we found a weak
indication that the risk of non-fatal self harm among users of the
SSRIs studied is highest in those who used paroxetine. This is in
keeping with the finding by Jick et al, of no substantial difference
in the effects of the antidepressants they studied on people aged
Table 1 Characteristics of study cohort according to first antidepressant class prescribed. Values are numbers (percentages) unless otherwise indicated
Characteristic SSRIs (n=90 403) Tricyclic antidepressants (n=50 829) Other antidepressants (n=4863) Total (n=146 095)
Age in years:
10-18 3830 (4) 1316 (3) 141 (3) 5287 (4)
19-30 23 561 (26) 10 145 (20) 1086 (22) 34 792 (24)
31-45 31 541 (35) 15 431 (30) 1548 (32) 48 520 (33)
46-60 18 310 (20) 11 506 (23) 989 (20) 30 805 (21)
61-75 7949 (9) 7538 (15) 605 (12) 16 092 (11)
76-89 5212 (6) 4893 (10) 494 (10) 10 599 (7)
Women 58 444 (65) 33 399 (66) 2924 (60) 94 767 (65)
Men 31 959 (35) 17 430 (34) 1939 (40) 51 328 (35)
Median (interquartile range) duration
of observation (years)
0.67 (0.57-1.03) 0.65 (0.57-1.02) 0.65 (0.57-1.02) 0.66 (0.57-1.03)
Severity of depression:
Mild 60 537 (67) 36 893 (72) 3306 (68) 100 736 (69)
Moderate 26 710 (30) 12 116 (24) 1329 (27) 40 155 (27)
Severe 3156 (3) 1820 (4) 228 (5) 5204 (4)
Referral to psychiatrist or
psychologist*
721 (1) 211 (0) 75 (2) 1007 (1)
History of self harm† 479 (1) 201 (0) 33 (1) 713 (<1)
Concomitant conditions:
Diagnosis of, or therapy for,
anxiety and panic disorders
21 501 (24) 11 209 (22) 1476 (30) 34 186 (23)
Schizophrenia 101 (0) 97 (0) 10 (0) 208 (0)
Antipsychotic therapy 2947 (3) 1916 (4) 252 (5) 5115 (4)
Drug misuse 61 (0) 45 (0) 3 (0) 109 (0)
Alcohol misuse 2408 (3) 1269 (2) 184 (4) 3861 (3)
*In year previous to index day.
†Includes drug overdose, poisoning, self laceration, and other non-fatal suicidal attempts before entry to cohort
Table 2 Age and sex distribution of cases of non-fatal self harm and suicide and their matched controls
Exposure
Non-fatal self harm Completed suicides
Cases (n=1968) Controls (n=34 494) Cases (n=69) Controls (n=1121)
Age at index date in years
10-18: 285 4567 0 0
Currently exposed to antidepressants 210 2809 0 0
Stopped antidepressants in previous 180 days 75 1758 0 0
19-30: 747 135 31 19 339
Currently exposed to antidepressants 482 7212 7 146
Stopped antidepressants in previous 180 days 265 6319 12 193
>30: 936 16 396 50 778
Currently exposed to antidepressants 652 9932 30 522
Stopped antidepressants in previous 180 days 284 6464 20 256
Women 1105 19 847 13 229
Men 863 14 647 56 892
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10 to 19 years, but that important differences could not be ruled
out.8
Limitations
Our study has several potential limitations that may have
influenced our results. A major concern in observational studies
is when the outcome under study is itself an indication for which
the drug might be prescribed.13 SSRIs are relatively non-toxic in
overdose14 compared with tricyclic antidepressants, and it is
therefore possible that they were selectively given to individuals
thought to be at higher risk of overdose and that SSRI overdose
did not result in admission to hospital or the patient presenting
at the general practice. Previous self harm is an important
predictor of further self harm and suicide.15 Although we had
information on recorded past self harm, the prevalence of such
behaviours among study members who harmed themselves
( < 5%) is considerably lower than reported among case series of
people who harmed themselves (50%)16 and completed suicides
(30% to 47%),17 which indicates the possibility of residual
confounding if non-fatal self harm is recorded differentially for
SSRIs compared with tricyclic antidepressants. Three other limi-
tations are worth noting. Firstly, we assumed prescribing to be a
marker for exposure, but not all prescriptions are dispensed, and
Table 3 Odds ratios for the association of potential confounders with non-fatal self harm and completed suicides
Variable
Non-fatal self harm Completed suicides
Cases
(n=1968)
Controls (n=34
494) Crude odds ratio (95% CI)* Cases (n=69)
Controls
(n=1121) Crude odds ratio (95% CI)
Severity of depression:
Mild 1260 22095 1 54 785 1
Moderate 601 11047 0.98 (0.88 to 1.08) 13 293 0.64 (0.33 to 1.22)
Severe 107 1352 1.43 (1.16 to 1.76) 2 43 —
Referral to psychiatrist or
psychologist†
202 891 4.10 (3.48 to 4.84) 6 26 3.41 (1.28 to 9.05)
History of self harm‡ 64 134 9.14 (6.73 to 12.4) 3 4 15.0 (3.36 to 67.0)
Diagnosis of, or treatment for,
anxiety or panic disorder
643 7888 1.67 (1.51 to 1.85) 19 228 1.60 (0.91 to 2.82)
Schizophrenia 2 8 1.82 (0.32 to 10.5) 1 3 —
Antipsychotic therapy 255 1908 2.40 (2.08 to 2.77) 12 46 4.67 (2.30 to 9.51)
Drug misuse 2 9 2.90 (0.61 to 13.8) 0 2 —
Alcohol misuse 213 1173 3.58 (3.04 to 4.21) 7 53 2.31 (0.97 to 5.49)
Lithium therapy§ 23 182 1.81 (1.16 to 2.83) 0 6 —
No of different antidepressants
prescribed§:
0 715 19 536 1 27 673 1
1 807 11 544 1.97 (1.77 to 2.19) 29 365 2.05 (1.18 to 3.59)
2 or 3 422 3232 3.65 (3.19 to 4.18) 12 82 3.42 (1.57 to 7.43)
>3 24 182 3.41 (2.18 to 5.33) 1 1 —
*Values not shown for age and sex as they were matching variables.
†In year before index day.
‡Includes drug overdose, deliberate poisoning, self laceration, and other methods of self harm before entry to cohort.
§In year before index day and since entry to cohort.
Table 4 Risk of non-fatal self harm and completed suicide in people prescribed SSRIs, other antidepressants, or exposed to more than one antidepressant
compared with people prescribed tricylic antidepressants and among specific SSRIs compared with paroxetine and specific tricyclic antidepressants compared
with dothiepin (all ages)
Exposure
Non-fatal self harm Completed suicides
Cases
(n=1344)
Controls
(n=19 953)
Crude odds ratio (95%
CI)
Adjusted odds ratio*
(95% CI)
Cases
(n=36)
Controls
(n=664)
Crude odds ratio (95%
CI)
Adjusted odds ratio*
(95% CI)
Any current use of
tricylic antidepressant
319 4901 1 1 15 201 1 1
Any current use of
SSRIs
854 13636 0.97 (0.85 to 1.12) 0.99 (0.86 to 1.14) 17 406 0.59 (0.28 to 1.27) 0.57 (0.26 to 1.25)
Other antidepressants 86 894 1.30 (1.01 to 1.68) 0.99 (0.76 to 1.29) 3 28 1.51 (0.39 to 5.85) 0.80 (0.16 to 4.06)
Co-exposure† 85 522 2.55 (1.96 to 3.31) 1.53 (1.15 to 2.04) 1 29 - -
Specific SSRIs:
Paroxetine 289 4209 1 1 8 135 1 1
Citalopram 128 1915 1.03 (0.83 to 1.29) 1.01 (0.80 to 1.26) 2 5 - -
Fluoxetine 304 5239 0.88 (0.74 to 1.04) 0.94 (0.79 to 1.11) 6 159 0.60 (0.20 to 1.81) 0.42 (0.13 to 1.39)
Fluvoxamine 42 810 0.74 (0.52 to 1.03) 0.73 (0.52 to 1.04) 0 29 - -
Sertraline 91 1463 0.92 (0.72 to 1.17) 0.86 (0.67 to 1.10) 1 33 - -
Specific tricyclic antidepressants:
Dothiepin 136 2334 1 1 7 102 1 1
Amitriptyline 66 926 1.21 (0.89 to 1.65) 1.18 (0.86 to 1.61) 2 31 - -
Lofepramine 68 1096 1.11 (0.82 to 1.50) 1.08 (0.79 to 1.47) 4 47 1.12 (0.30 to 4.20) 0.94 (0.24 to 3.61)
Other tricylic
antidepressant
49 545 1.43 (1.01 to 2.02) 1.19 (0.83 to 1.69) 2 21 - -
*Adjusted for severity of depression; time depression was diagnosed in relation to start of therapy; referral to psychiatrist or psychologist before index day; history of self harm; diagnosis of, or
treatment for, anxiety or panic disorder; schizophrenia; antipsychotic drugs; drug misuse; and alcohol misuse.
†Any exposure to more than one antidepressant of same class or different classes.
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some of those dispensed are not taken. Greater compliance with
SSRIs may distort our comparison of their risks compared with
those associated with tricyclic antidepressants. Secondly, we have
carried out a large number of hypothesis tests so that some asso-
ciations we have highlighted may be chance findings. Thirdly, we
did not deal with the question of whether people treated with
SSRIs are at greater risk of self harm than those with equivalent
morbidity who do not receive treatment. We have assessed risk
only relative to people receiving tricyclic antidepressants.
Representativeness of the study
As expected in a cohort of incident depression, the suicide rate in
our study (62 per 100 000 patient years) was higher than in the
general population (9 per 100 000 people).11 18 Of note, no
suicides occurred among people receiving antidepressants and
younger than 19 years. The incidence of non-fatal self harm was
seven times higher than that of around 400/100 000 in 1995
reported in Oxford.19 The ratio of cases of non-fatal to fatal self
harm (approximately 30:1) in our study approximates to the
ratio of the estimated number of hospital presenting episodes of
self harm (n = 142 000)19 and suicides in the general population
of England and Wales (n = 5000).20
Potential biases
Our findings for people younger than 19 are consistent with the
results from randomised controlled trials, which have shown an
increased risk of suicidal behaviour in children and adolescents
exposed to SSRIs5 6 but may have resulted from confounding by
indication. For example, personality disorders and adjustment
disorders are particularly associated with self harm, and in
primary care, such patients may be given a diagnosis of depres-
sion and SSRIs may be prescribed preferentially. The adjustment
made for previous episodes of self harm may not fully compen-
sate for a bias introduced in this way.
Strengths of the study
The main strengths of our study are the large sample size,
detailed exposure data, and confounder information. The base
population used in our study partly overlaps with that used by
Jick et al.8 However, their study included patients prescribed anti-
depressants between 1993 to 1999, whereas ours covered 1995
to 2001 and considered only patients with a first prescription of
antidepressants in this period. Furthermore, our approach to the
ascertainment of cases of non-fatal self harm and suicides
yielded almost four times as many cases, giving us considerably
more power than previous studies.
We have endeavoured to control as closely as possible for
factors that may be associated both with the risk of suicidal
behaviour and the choice of antidepressant. This was also the
rationale for the restriction of the study cohort to patients with a
first recorded episode of depression and for the comparisons
Table 5 Risk of non-fatal self harm and suicide in relation to time since starting tricyclic antidepressant monotherapy or SSRI monotherapy (all ages)*
Exposure
Non fatal self harm Completed suicides
Cases
(n=1173)
Controls (n=18
537)
Crude odds ratio (95%
CI)
Adjusted odds ratio*
(95% CI)
Cases
(n=29)
Controls
(n=607)
Crude odds ratio (95%
CI)
Adjusted odds ratio*
(95% CI)
≤14 days:
Tricyclic
antidepressants
118 1643 1 1 5 48 1 1
SSRIs 242 4214 0.76 (0.60 to 0.97) 0.77 (0.61 to 0.98) 5 117 0.51 (0.12 to 2.08) 0.45 (0.10 to 2.06)
15-30 days:
Triyclic
antidepressants
67 1231 1 1 1 36 — —
SSRIs 208 3482 1.10 (0.82 to 1.48) 1.11 (0.82 to 1.49) 4 69 — —
31-60 days:
Tricyclic
antidepressants
77 1183 1 1 5 87 1 1
SSRIs 233 3395 1.10 (0.84 to 1.44) 1.17 (0.88 to 1.54) 4 144 0.49 (0.12 to 1.95) 0.44 (0.10 to 2.01)
>60 days:
Tricyclic
antidepressants
57 844 1 1 4 30 1 1
SSRIs 171 2545 1.08 (0.79 to 1.49) 1.08 (0.78 to 1.50) 4 76 0.39 (0.08 to 1.86) 0.33 (0.07 to 1.66)
*Participants exposed to more than one antidepressant or prescribed non-SSRI, non-tricyclic antidepressants (see table 4) included in models but, for presentational purposes, data are not given
in table.
†Adjusted for severity of depression; time depression was diagnosed in relation to start of therapy; referral to psychiatrist or psychologist before index day; history of self harm; diagnosis of, or
treatment for, anxiety or panic disorder; schizophrenia; antipsychotic drugs; drug misuse; and alcohol misuse.
Table 6 Risk of non-fatal self harm in people prescribed SSRIs compared with tricyclic antidepressants in relation to age
Exposure
Non-fatal self harm
Cases (n=1344) Controls (n=19 953) Crude odds ratio (95% CI) Adjusted odds ratio* (95% CI)
10-18 years†:
Any current use of tricyclic antidepressants 24 493 1 1
Any current use of SSRIs 168 2148 1.73 (1.10 to 2.72) 1.59 (1.01 to 2.50)
19-30 years:
Any current use of tricyclic antidepressants 106 1687 1 1
Any current use of SSRIs 312 5013 1.00 (0.79 to 1.27) 1.04 (0.82 to 1.32)
>30 years:
Any current use of tricyclic antidepressants 189 2721 1 1
Any current use of SSRIs 374 6475 0.83 (0.69 to 1.01) 0.86 (0.71 to 1.04)
Participants exposed to more than one antidepressant or prescribed non-SSRI, non-tricyclic antidepressants (see table 4) were included in models but, for presentational purposes, data are not
given in table.
*Adjusted for severity of depression; time depression was diagnosed in relation to start of therapy; referral to psychiatrist or psychologist before index day; history of self harm; diagnosis of, or
treatment for, anxiety or panic disorder; schizophrenia; antipsychotic drugs; drug misuse, and alcohol misuse.
†Includes nine cases of non-fatal self harm and 86 controls exposed to SSRIs, and no cases and 18 controls exposed to tricyclic antidepressants among patients aged 10 to 14 years.
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within drug classes, thereby minimising confounding by
indication operating at a class level.
Conclusion
As prescribing to adults accounts for over 95% of antidepressant
use in the United Kingdom, our finding that SSRIs and tricyclic
antidepressants have a similar risk profile with respect to suicide
and non-fatal self harm is reassuring. It is possible, however, that
any adverse or protective effects are common to all classes of
antidepressants. Further research, based on large randomised
trials, should assess the long term and short term risk and ben-
efits of antidepressants and compare these with non-
pharmacological therapies for depression in adults.
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Fig 1 Risk of non-fatal self harm in patients aged 10-18 currently exposed to
citalopram, fluoxetine, fluvoxamine, and sertraline compared with paroxetine
What is already known on this topic
Selective serotonin reuptake inhibitors (SSRIs) are the most
commonly prescribed class of antidepressant.
Evidence from recent clinical trials shows that SSRIs may
increase the risk of self harm and suicidal thoughts in
children and adolescents
Previous studies of the risk of suicide in adults have been
restricted to the four most frequently prescribed
antidepressants and have lacked statistical power to identify
whether risks differ in children compared to adults
What this study adds
Risks of self harm and suicide were no different in adults
prescribed SSRIs compared with those prescribed tricyclic
antidepressants.
Children and adolescents prescribed SSRIs seemed possibly
to be at increased risk of self harm compared with those
prescribed tricyclic antidepressants
No children taking antidepressants in this study committed
suicide
The absence of excess risk of self harm in adult users of
SSRIs may be interpreted as reassuring evidence of their
safety or that any adverse or protective effects of SSRIs are
no different from those seen with other antidepressants.
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